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ABSTRACT

ARTICLE HISTORY

Chronic inflammatory skin disorders are frequently associated with impaired skin barrier function.
Selective phosphodiesterase-4 (PDE4) inhibition constitutes an effective therapeutic strategy for
the treatment of inflammatory skin diseases. We now report the pharmacological antiinflammatory profile of DRM02, a novel pyrazolylbenzothiazole derivative with selective in vitro
inhibitory activity toward PDE4 isoforms A, B and D. DRM02 treatment of cultured primary human
and mouse epidermal keratinocytes interfered with pro-inflammatory cytokine production elicited
by interleukin-1α and tumor necrosis factor-α. Similarly, DRM02 inhibited the production of proinflammatory cytokines by human peripheral blood mononuclear cells ex vivo and cultured THP-1
monocyte-like cells, with IC50 values of 0.6–14 µM. These anti-inflammatory properties of DRM02
were associated with dose-dependent repression of nuclear factor-κB (NF-κB) transcriptional
activity. In skin inflammation in vivo mouse models, topically applied DRM02 inhibited the acute
response to phorbol ester and induced Th2-type contact hypersensitivity reactivity. Further,
DRM02 also decreased cutaneous clinical changes and expression of Th17 immune pathway
cytokines in a mouse model of psoriasis evoked by repeated topical imiquimod application.
Thus, the overall pharmacological profiling of the PDE4 inhibitor DRM02 has revealed its potential
as a topical therapy for inflammatory skin disorders and restoration of skin homeostasis.
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Introduction
The skin plays indispensable roles as an immune and
physical barrier, and is a first line of defense against
pathogens and environmental challenges. The etiology of a number of common dermatological diseases
includes prominent inflammatory and immune
components.1 Indeed, inflammatory skin diseases
are major health issues, as they constitute the most
common problem in dermatology.2 Although acute
inflammation contributes to the homeostatic protective and regenerative properties of the skin, inflammatory memory is retained in epidermal stem cells
and may contribute to recurrent skin inflammation
and development of maladaptive responses.3
Therapies for chronic inflammatory cutaneous diseases, such as atopic dermatitis and psoriasis, often
include the use of corticosteroids or calcineurin inhibitors. Topical corticosteroids are highly effective, but
adverse consequences, including skin atrophy,
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systemic absorption, and suppression of the hypothalamic-pituitary-adrenal axis, limit their long-term
use.4 Topical calcineurin inhibitors interfere with
T-lymphocyte and dendritic cell activation, and have
been used as a second-line therapy for short-term or
intermittent treatment. Limitations of calcineurin
inhibitors include contraindication in immunocompromised individuals, and the relatively common
occurrence of burning or stinging with application,
which negatively affects patient compliance.4 Over the
past two decades, phosphodiesterases (PDE) have also
emerged as druggable targets in the treatment of
inflammatory skin disorders.5
Within the superfamily of PDE enzymes, the
type-4 (PDE4) family is a major player in the
regulation of cellular pro-inflammatory responses.
PDE4 exerts key roles in inflammatory disorders,
and is relatively abundant in myeloid and lymphoid cells.6,7 Several PDE4 isoforms are also
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expressed in epidermal keratinocytes.8 PDE4 catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP), thereby inactivating this second
messenger.6 Inhibition of PDE4 increases cAMP
levels, which, in turn, interferes with proinflammatory processes in epidermal cells
in vitro, and in preclinical in vivo models of cutaneous inflammatory disorders.9–11 Several PDE4
inhibitors, including apremilast and cilomilast,
are now clinically used to decrease the expression
of key pro-inflammatory cytokines, including
tumor necrosis factor (TNF) α, interleukin (IL)-6,
IL-17 and IL-23.7,9,11,12 However, there remains an
ongoing need for the introduction of effective
novel anti-inflammatory drugs, as some clinically
approved PDE4 inhibitors can also exert doselimiting systemic toxicities.13
In the present study, we describe the pharmacological effects of DRM02, a novel and selective PDE4
inhibitor. DRM02 interferes with pro-inflammatory
cytokine production in response to a wide variety of
stimuli both in epidermal and in immune cells.
Furthermore, we also demonstrate the effectiveness
of DRM02 in several mouse models of skin inflammation elicited by a variety of agents.

Results
Activity profiling of DRM02

DRM02 is a pyrazolylbenzothiazole derivative
(Figure 1a), which we developed as a potential topical
anti-inflammatory reagent. To identify the principal
targets of DRM02 modulation, this compound was
first profiled against >600 proteins in cell-free activity
assay panels containing various human cellular
enzymes, including PDE subtypes, kinases, phosphatases, and receptor kinases. In these assays, DRM02
decreased U937 cell-derived PDE4 activity with a halfmaximal inhibitory concentration (IC50) of 0.4 μM
(Figure 1b). DRM02 also decreased kinase activity
present in immunoprecipitates containing exogenously expressed human integrin-linked kinase (ILK)
isolated from Hi-5 insect cells, with a mean IC50 of
20.6 nM (Figure 1c). DRM02 had no significant activity at concentrations lower than 1.0 μM against any of
the other proteins evaluated.
To further characterize the modulatory activity of
DRM02 toward phosphodiesterases, we next

interrogated a panel of purified and recombinant
human PDE enzymes. Using similar in vitro assays,
we found that DRM02 effectively inhibited PDE4A,
PDE4B and PDE4D isoforms with IC50 values of
0.64 μM, 0.44 μM and 0.63 μM, respectively (Figure
1d). Notably, DRM02 was substantially less potent
against PDE3A, PDE3B and PDE7A, and did not
significantly affect the activity of PDE1B, PDE2A,
PDE5, PDE6, PDE8A, PDE10A or PDE11A (Figure
1d). Collectively, these results identify DRM02 as
a selective inhibitor of the PDE4 isoforms A, B and D.
DRM02 is a potent inhibitor of pro-inflammatory
cytokine expression in epidermal keratinocytes

In the epidermis, keratinocytes are both key cellular
targets for and producers of pro-inflammatory mediators, contributing to the activation of self-sustaining
inflammatory loops.14 We examined the effect of
DRM02 on inflammatory cytokine expression in primary cultured human epidermal keratinocytes stimulated with IL-1α, which induces expression of multiple
pro-inflammatory factors in these cells. Four hours
after IL-1α addition to the culture medium, we
observed increases in cellular IL8, TNF and GM-CSF
mRNA levels of approximately 10-, 25- and 18-fold,
respectively (Figure 2a–c). The presence of DRM02
attenuated the stimulatory effects of IL-1α on IL8,
TNF and GM-CSF transcript levels in a dosedependent fashion, with IC50 values in the 3–20 μM
range for IL8 and GM-CSF, and 10–30 μM for TNF.
The glucocorticoid dexamethasone and the calcineurin inhibitor FK506, two potent antiinflammatory drugs, had lesser or no effects on the
levels of these mRNA species (Figure 2a–c). IL8, TNF
and GM-CSF mRNA levels remained 10- to 20-fold
higher after 24 h of IL-1α treatment, relative to those
in cultures without IL-1α stimulation, and significant
reductions in those levels persisted in the presence of
DRM02 (data not shown). In the culture medium of
non-stimulated keratinocytes, low granulocytemacrophage colony-stimulating factor (GM-CSF)
concentrations were detected (~ 100 pg/ml), but
these levels increased substantially by stimulation
with IL-1α. Significantly, DRM02 was a more potent
inhibitor of IL-1α-induced increases in GM-CSF in
culture medium (IC50 ~ 3 μM) than FK506 (IC50
~ 20 μM, Figure 2d). DRM02 also effectively dampened increases in GM-CSF secretion into culture
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Figure 1. Pharmacological activity of DRM02 in vitro.
(a) Chemical structure of the pyrazolylbenzothiazole derivative DRM02 (molecular weight 341.4). (b) The effect of increasing
concentrations of DRM02 on PDE4 enzymatic activity, which measured formation of [3 H]5ʹ-AMP from [3 H]cAMP in the presence
of 1 mM cAMP, was assessed using PDE4 purified from human U-937 cells. The mean level of [3 H]5ʹ-AMP formed after 60 min was
measured. An IC50 value of 400 nM for DRM02 inhibition of PDE4 activity in this assay was determined (n = 3). (c)
Phosphotransferase activity was assessed in immunoprecipitate complexes containing recombinant ILK-GST fusion proteins isolated
from Hi-5 insect cells. DRM02 was titrated against phosphotransferase activity in a radioactive biochemical assay using the S6 kinase
sub-peptide KRRRLASLR as the target substrate. DRM02 inhibited phosphotransferase activity with a mean IC50 value of
20.6 ± 15.2 nM, as determined from independent analyses of seven different DRM02 synthesis lots. A representative doseresponse curve from one of these phosphotransferase assays is shown. (d) Mean IC50 values for inhibition of DRM02 of enzymatic
activity of the indicated PDE4 isoforms, measured as described for panel (B). N. D., not determined.

medium by keratinocytes stimulated with TNFα,
epidermal growth factor (EGF), transforming
growth factor-α (TGFα), or with IL-1α/EGF, IL-1α/
TGFα, TNFα/EGF or TNFα/TGFα combinations
(Supplemental Figure 1).

ILK is dispensable for the anti-inflammatory
effects of DRM02

We next determined if ILK is involved in the
observed anti-inflammatory properties of
DRM02 in keratinocytes. To this end, we
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Figure 2. DRM02 inhibition of inflammatory cytokine expression in human epidermal keratinocytes.
(a-c) Cultured primary human keratinocytes were either not stimulated (NS) or treated with IL-1α in the presence of the indicated
concentrations of DRM02, dexamethasone (DEX) or FK506. After 4 h, cells were processed and total RNA was isolated. The
abundance of mRNA transcripts for the indicated cytokines was measured by RT-qPCR. Cytokine CT values were normalized to
GAPDH1 CT determinations for each mRNA preparation. mRNA CT values from control keratinocytes treated with IL-1α plus 0.15%
DMSO were 0.044 ± 0.008, 0.050 ± 0.001 and 0.115 ± 0.024 for GM-CSF, IL8 and TNFA, respectively. The results are expressed as the
mean percentage + SD, relative to the average value of mRNA levels in control cultures (n = 3). *P < .05 and **P < .01 versus mRNA
levels in control samples (one-way ANOVA with Dunnett’s multiple comparisons test). (d) Human epidermal keratinocytes were
either not stimulated (◯, ●) or treated with IL-1α (◺, ∎), in the presence of DRM02 (open symbols) or FK506 (closed symbols). The
levels of GM-CSF present in the culture medium after 48 h of incubation were measured by ELISA. The results are expressed as the
mean + SD of three determinations. *P < .05 and **P < .01 levels in samples treated with vehicle and IL-1α (one-way ANOVA with
Dunnett’s multiple comparisons test). Results from one of four identically performed experiments giving closely similar concentration-dependent DRM02-induced GM-CSF inhibition are shown.

compared the responses to IL-1α/TNFα of primary keratinocytes isolated from mice with epidermis-specific inactivation of the Ilk gene
(hereafter termed ILKKO) and ILK-expressing
littermates
(hereafter
termed
ILK+).15
Stimulation with IL-1α and TNFα increased the
levels of secreted CXCL1, the mouse orthologue
of human IL-8, by ~23- and ~8-fold, respectively, in ILK+ and ILKKO cells, and these
increases were insensitive to the presence of
dexamethasone (Figure 3a). In contrast, DRM02

impaired stimulation of CXCL1 in a dosedependent manner in all cultures tested, irrespective of whether or not the cells expressed
ILK (Figure 3b). IL-1α/TNFα treatment also
increased levels of secreted GM-CSF in both
cell types, and these increases were sensitive to
inhibition by dexamethasone and by DRM02
(Figure 3c,d). No reduction in viability was
observed in either cell type with any of these
treatments (data not shown). These data indicate
that ILK is not necessary for keratinocyte
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Figure 3. ILK-independent inhibition of pro-inflammatory cytokine expression by DRM02.
ILK-expressing (ILK+) or ILK-deficient (ILKKO) primary mouse keratinocyte cultures were treated with IL-1α and TNFα (25 ng/ml, each),
in the presence or absence of 1 μM dexamethasone (DEX, panels a, c) or with the indicated concentrations of DRM02 (panels b, d).
Twenty-four hours later, the levels of CXCL1 or GM-CSF present in the culture medium were measured by ELISA. For each treatment
condition, the corresponding background CXCL1 or GM-CSF levels determined for non-stimulated cells was subtracted. Cytokine
levels are plotted as concentrations in ng/ml or pg/ml (panels a, c) or as the percentage of values obtained for ILK+ or ILKKO
keratinocytes stimulated with IL-1α and TNFα in the presence of DMSO vehicle. The results represent the mean + SD of three
determinations, using independent cell isolates. *P < .05 relative to non-stimulated cells (one-way ANOVA with Dunnett’s multiple
comparisons test). n.d. not detectable.

inflammatory responses to IL-1α/TNFα or for
the pharmacological action of DRM02 in this
model.

DRM02 inhibits expression of
inflammation-regulating factors in THP-1 and in
peripheral blood mononuclear cells (PBMC)

Antigen-presenting cells, including monocytes
and macrophages, can enter the skin from the
peripheral circulation, playing key roles in initiating and modulating cutaneous inflammation.16
Hence, we further characterized the effects of
DRM02 on responses that model inflammatory

conditions, using THP-1 monocyte-like cells and
human PBMC from healthy donors.
THP-1 cells pre-treated with vehicle or with
increasing concentrations of DRM02 were then
stimulated with lipopolysaccharide (LPS) and
interferon (IFN)-γ for 48 h, to increase cytokine
production that reflects pro-inflammatory M1
macrophage polarization in vitro.17 Under these
conditions, DRM02 decreased levels of secreted
TNFα, IL-1β, IL-6 and IL-8 in a dose-dependent
manner, with IC50 values in the 1.4–9.0 μM
range (Table 1). DRM02 concentrations as high
as 30 μM were without effect on THP-1 cell
viability or proliferation (Table 1 and data not
shown).
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Table 1. DRM02 inhibits proliferation and cytokine expression
of stimulated PBMC and THP-1 cells. PBMC were stimulated
with either phytohemagglutinin (PHA; 1 μg/ml) or the combination of LPS (10 ng/ml) plus IFNγ (33 ng/ml). THP-1 monocytelike cells were treated with LPS (10 ng/ml) plus IFNγ (100 ng/
ml). Conditioned cell culture media were collected after
48 hours, and were analyzed to determine cytokine levels
using bead arrays and flow cytometry. DRM02 IC50 determinations are expressed as the mean ± SD for each test parameter.
The number or experiments is indicated in parentheses. ND, not
determined.
DRM02 IC50 (μM)
THP-1 cells
PARAMETER
Proliferationa
TNFαb
IFNγa
IL-1βb
IL-6b
IL-8b
IL-10b
IL-12 p70b

LPS/IFNγ
>30 (17)
1.4 ± 0.9 (19)
ND
3.8 ± 2.6 (7)
9.1 ± 4.0 (19)
5.6 ± 2.5 (18)
ND
ND

PBMC
LPS/IFNγ
2.9 ± 1.4 (3)
0.6 ± 0.4 (11)
ND
4.4 ± 1.7 (10)
10.8 ± 3.7 (11)
14.5 ± 4.4 (7)
ND
0.6 ± 0.4 (10)

PHA
2.2 ± 1.2 (7)
0.4 ± 0.2 (11)
1.2 ± 0.6 (11)
ND
ND
ND
3.2 ± 1.2 (11)
ND

a 3
b

[ H]dThd incorporation into DNA
Secreted cytokine into cell culture medium

To complement these studies using primary cells,
we next examined the effect of DRM02 on proinflammatory responses of normal human PBMC
ex vivo, stimulated with either an LPS/IFN-γ combination or the mitogen phytohemagglutinin. Both
LPS/IFNγ and phytohemagglutinin promoted cell
proliferation, which was sensitive to inhibition by
DRM02, as evidenced by the ability of this drug to
reduce [3 H] thymidine ([3 H]dThd) incorporation
into DNA, with IC50 values of 2.90 ± 1.4 μM and
2.2 ± 1.2 μM, respectively (Table 1). In addition to
functioning as potent mitogens in PBMC, these
agents also induce secretion of pro-inflammatory
cytokines.18 DRM02 decreased LPS/IFNγ-induced
secretion of TNFα, IL-1β, IL-6, IL-8 and IL-12p70
(mean IC50 0.6 μM–14.5 μM; Table 1). Similarly,
stimulation of PBMC with phytohemagglutinin
resulted in DRM02-sensitive secretion of TNFα,
IFNγ and IL-10, with IC50 values for DRM02 inhibition in the low micromolar range (Table 1). Thus,
DRM02 efficiently lowered pro-inflammatory signatures of activated PBMC and THP-1 cells.

Inhibition of NF-κB activity by DRM02

NF-κB is a central component of pro-inflammatory
signaling pathways activated by cytokines such as
TNFα and IL-1.19 Cellular NF-κB activation by

TNFα and IL-1 occurs through a canonical pathway
that involves activation of IκB kinase (IKK) and IκB
dissociation from NF-κB. Free NF-κB dimers then
translocate from the cytoplasm to the nucleus to
activate transcription of pro-inflammatory and
other target genes (reviewed in20). Interactions
between the cAMP and NF-κB pathways have
been reported for many cell types, including keratinocytes, monocytes, THP-1 and HEK293 cells.20 To
determine the effects of DRM02 on NF-κB transcriptional activity, we used a HEK293-derived line
that stably maintains a chromosomal integration of
a luciferase reporter construct regulated by multiple
copies of the NF-κB response element, hereafter
termed 293-Luc cells. Treatment with TNFα
increased luciferase activity by approximately 100fold, relative to unstimulated cells (Supplemental
Figure 2). The presence of DRM02 interfered with
this induction in a dose-dependent manner, with
IC50 and IC90 values of ~7 μM and ~30 μM, respectively, without measurable effects on cell viability
(Supplemental Figure 2). For comparison, treatment
with the well-established NF-κB inhibitor
quinazoline21 at the highest test concentration that
did not induce cytotoxicity (10 μM) decreased
TNFα-induced, NF-κB-dependent luciferase output
by ~43% (Supplemental Figure 2).

Inhibition of intercellular adhesion molecule-1
(ICAM-1) expression by DRM02

In the skin, certain pro-inflammatory stimuli
induce expression of adhesion molecules, which
are important contributors to the entry and persistence of immune cells in affected sites. ICAM-1 is
a cell surface glycoprotein present in epithelial,
endothelial and immune cells. In epidermal keratinocytes, ICAM-1 is an adhesion molecule that
serves as a ligand for the leukocyte adhesion protein
LFA-1, facilitating their interactions with infiltrating leukocytes.22 Significantly, ICAM-1 expression
can be up-regulated through the canonical NF-κB
signaling pathway.20 Because DRM02 interfered
with NF-κB transcriptional activity, and given that
changes in ICAM-1 expression substantially influence the course of inflammatory and immune
responses in the skin,22 we next examined the
effects of DRM02 on inflammation-induced
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ICAM-1 expression in human epidermal HaCaT
keratinocytes.
Stimulation of HaCaT cells with TNFα (10 ng/
ml), IFNγ (2.5 ng/ml) or both cytokines increased
cell surface levels of ICAM-1 by approximately 20-,
10- and >100-fold above those in non-stimulated
cells, respectively (Figure 4a). The presence of
DRM02 attenuated in a dose-dependent manner
the increases in ICAM-1 surface levels induced by
TNFα alone or in combination with IFNγ, achieving
a 75% reduction at a concentration of 20 μM (Figure
4b,c). Under these conditions, the effect of DRM02
was distinct from that of dexamethasone, which did
not alter increases in surface ICAM-1 levels induced
by TNFα or TNFα/IFNγ combinations (Figure 4b,c).
Similarly,
DRM02
induced
concentrationdependent decreases in surface ICAM-1 levels in
HaCaT cells treated with IL-1β/TNFα or IL-1β/
IFNγ combinations, although it was relatively ineffective against surface ICAM-1 increases produced
by treatment with IFNγ alone (Supplemental
Figure 3).
Under inflammatory conditions, monocyte
expression of ICAM-1 and other adhesion molecules is also activated.23,24 Thus, we next explored
the ability of DRM02 to modulate ICAM-1 expression in stimulated THP-1 cells. To this end, we
incubated the cells with TNFα, LPS, polyinosinic:
polycytidylic acid (poly I:C), or peptidoglycan
(PGN) and observed 14- to 39-fold increases in
surface ICAM-1 levels, relative to non-stimulated
cells (Figure 4d). DRM02 (10 μM) suppressed
these increases in ICAM-1 levels by 35%-45%.
Similar to HaCaT cells, DRM02 was without effect
on enhanced surface ICAM-1 levels induced by
IFNγ (Figure 4d). Collectively, these data indicate
that DRM02 effectively interferes with ICAM-1
induction by a broad range of pro-inflammatory
stimuli, both in epithelial and in immune cell
types.
DRM02 inhibition of LPS-induced inflammation
in vivo

Activated macrophages release pro-inflammatory
mediators through activation of NF-κB and other
pathways.25 Aberrant macrophage responses contribute to various inflammatory disorders, and,
therefore, their pharmacological modulation has
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untapped therapeutic potential. Macrophages activated by bacterial LPS exhibit multiple responses,
including increased secretion of inflammatory
mediators and expression of adhesion molecules
representing a characteristic “inflammation
signature”.26 Given the range of anti-inflammatory
properties of DRM02 observed in cultured cells, we
next investigated whether DRM02 might exert protective effects on systemic inflammatory responses
in vivo. To this end, we administered LPS intravenously (i.v. 1 mg/kg body weight) to mice pretreated with control vehicle or with DRM02, and
determined serum concentrations of various cytokines and other factors at timed intervals thereafter.
TNFα, IFNγ, GM-CSF, macrophage chemoattractant protein-1 (MCP-1), IL-6 and IL-10
were undetectable in serum samples prepared
from naive mice or from animals given PBS. In
contrast, TNFα, IL-6 and GM-CSF were readily
detected in serum as early as 1.5 h post-LPS injection (Figure 5). DRM02 pretreatment (50 mg/kg
body weight) significantly mitigated LPS-mediated
increases in serum levels of these three cytokines
by 60%-80% (Figure 5). Increases in IFNγ levels
were observed 4 h following LPS administration,
and they were similarly reduced by DRM02
(Figure 5). Notably, the magnitude of DRM02
reduction in cytokine serum levels was comparable
to that observed in mice treated with dexamethasone, albeit a lower dose of dexamethasone was
used due to the combination of dexamethasone
solubility and maximum volume restrictions for
s.c. administration in mice (Figure 5). However,
unlike dexamethasone, DRM02 also increased
serum levels of the anti-inflammatory cytokine
IL-10 within the time frame of these experiments
(Figure 5). Neither DRM02 nor dexamethasone
modulated LPS-mediated increases in MCP-1
serum levels (Figure 5). These studies indicate
that that DRM02 effectively attenuates systemic
expression of a variety of pro-inflammatory factors
following exposure to intravenous LPS.
Topical DRM02 inhibits acute irritant dermatitis
and T-helper type 2 (Th2) contact
hypersensitivity in mice

Skin inflammation can be induced in mouse models by a single topical dose of phorbol myristate
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Figure 4. DRM02 inhibition of ICAM-1 expression.
(a) Representative flow cytometry ICAM-1 (CD54PE) surface expression profiles for untreated HaCaT cells or cells stimulated with
TNFα (10 ng/ml), IFNγ (2.5 ng/ml) or both cytokines at the indicated concentrations, for 48 h. Mean channel fluorescence intensity
(MCFI) values are shown for each sample in brackets. For non-stimulated HaCaT cells, mean MCFI values for anti-ICAM-1 antibody
stained cells averaged 20.0 ± 13.4 (arbitrary units, AU, n = 5), whereas following 48 hours of TNFα, IFNγ or TNFα/IFNγ treatment,
MCFI values averaged 259.0 ± 89.6 AU (n = 5), 115.5 ± 46.0 AU (n = 3) and 1139 ± 335 AU (n = 3), respectively. (b) HaCaT cells were
pre-treated with the indicated concentrations of DRM02 for 1 h, and then stimulated with the indicated factor. After 48 h, ICAM-1
surface expression profiles were determined as in panel (a). (c) HaCaT cells were pretreated with the indicated concentrations of
DRM02 or dexamethasone (DEX) for 1 h, followed by addition of TNFα (10 ng/ml). After 48 h, ICAM-1 surface expression profiles were
determined by flow cytometry, as in panel (a). The histograms represent mean MCFI values + SD (n = 5), relative to MCFI levels
determined for cells stimulated with cytokines in the absence of DRM02 or DEX, which is set to 100%. **P < .01 versus control result
(one-way ANOVA and Dunnett’s multiple comparisons test). (d) THP-1 cells were pretreated for 1 h with vehicle or with DRM02, and
then stimulated for 48 h with the indicated. ICAM-1 surface expression levels were determined by flow cytometry. The results are
expressed as the ratio of the MCFI value determined in cells stimulated with the different factors divided by the MCFI units obtained
for non-stimulated cells stained with anti-ICAM-1 antibody. Without stimulation, MCFI values for anti-ICAM-1 stained cells averaged
5.3 ± 3.4 AU. With TNFα, LPS, poly I:C, PGN or IFNγ stimulation in the absence of further treatments, MCFI values were 134.6 ± 50.0,
167.8 ± 83.5, 83.6 ± 83.7, 114.6 ± 64.5 and 83.5 ± 30.9 AU (mean + SD), respectively. * P < .05, ***P < .005 versus vehicle control
(paired two-tailed t-tests, n = 4–6 independent experiments per treatment).
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Figure 5. Systemic administration of DRM02 modulates serum levels of inflammatory mediators in LPS-challenged mice.
Thirty minutes prior to i.v. LPS challenge (1 mg/kg), mice were administered dexamethasone (DEX, s.c.), DRM02 (i.p.) or matched
vehicle. Groups of 5–6 mice were sacrificed at the indicated times after LPS dosing, and serum was collected. Serum samples were
analyzed for the indicated cytokines, using bead arrays and flow cytometry (panels a-e), or ELISA (panel f). The data are shown as
mean serum values + SD. Similar treatment response patterns for these different factors were observed in one or more additional
experiments. *P < .05, **P < .01 versus vehicle control result (one-way ANOVA and Dunnett’s multiple comparisons test).

acetate (PMA). This acute inflammatory reaction,
termed irritant contact dermatitis (ICD), is characterized by epidermal erythema, edema, and
inflammatory cell infiltration.1 To explore the
anti-inflammatory activity of DRM02 in the skin,
we next assessed its effects on ear edema associated with PMA-induced ICD in mice. Auricles
of mice were treated with PMA, followed 3 h later
by DRM02 or matched vehicle, and ear thickness
was measured 24 h after the initial PMA treatment. The average increase in auricular thickness

caused by PMA with no additional treatment was
0.6 mm (Figure 6a). In four independent experiments using groups of 6 PMA-treated mice each,
topical application of a 20 mM DRM02 solution
reduced ear swelling by 55.3 ± 10.1%. In comparison, auricular thickness in animals treated with
dexamethasone (6.6 mM) was reduced by
38.7 ± 7.0% (Figure 6a).
Contact hypersensitivity (CHS) is an inflammatory skin reaction mediated by T cells, which can be
elicited in mice by cutaneous exposure to fluorescein
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Figure 6. Topical DRM02 inhibits PMA-induced skin inflammation and contact hypersensitivity responses to FITC.
(a) Mice were topically treated on the ears with PMA (0.02%), and 3 h later they received either no additional treatment (None) or
topical application of control vehicle, DRM02 (20 mM) or dexamethasone (DEX, 6.6 mM). Ear thickness was measured 21 hours
following test drug dosing. The data are presented as the mean change in ear thickness from baseline + SD (6 mice per group). In
four identically-performed experiments, highly similar results were obtained. (b) Twenty days following initiation of FITCsensitization, mice were challenged with FITC on one ear. Two hours later, the ears received no additional treatment (None),
control vehicle, DRM02 (50 mM) or DEX (2.5 mM). Ear measurements were conducted 24 hours after FITC challenge (i.e., 22 hours
following drug treatment). The data are presented as the mean + SD increase in ear thickness from baseline (6 mice per group). Four
identically-performed experiments gave similar results. ***P < .001 from vehicle control values (one-way ANOVA and Dunnett’s
multiple comparisons test).

isothiocyanate (FITC).27 Similar to human allergic
contact dermatitis, FITC-induced CHS consists of
a sensitization and an elicitation phase, characterized
by local infiltration of Th2 helper type
lymphocytes.27 To investigate the activity of
DRM02 in FITC-induced CHS, we first sensitized
mice by exposure to topical FITC on abdominal skin
four times over a period of two weeks. The animals
were then challenged by topically applying FITC on
the ears, followed 2 h later by DRM02 treatment. We
measured ear thickness 24 h after FITC challenge,
and determined that auricular thickness on average
had increased by about 0.42 mm, relative to the
mean pre-treatment thickness of 0.25 mm. FITCinduced changes in ear thickness were 42.6% ±
6.6% lower upon treatment with DRM02 (Figure
6b). For comparison, we also treated FITCchallenged mice with dexamethasone, and observed
a 90.3 ± 3.8% reduction in ear swelling (Figure 6b).
Collectively, these observations indicate that DRM02
interferes with both acute and hypersensitivityassociated pro-inflammatory processes in the skin.

DRM02 suppresses imiquimod-induced skin
inflammation in mice

Repeated topical application of imiquimod to mouse
skin induces psoriasiform dermatitis, characterized
by TNFα-dependent development of inflamed scaly
lesions driven by the IL-23/IL-17 immune axis,
which resemble human plaque-type psoriasis.28–30
To examine the ability of DRM02 to modulate psoriasiform inflammation, we topically administered
5% imiquimod thrice to mouse dorsal skin, at 24to 26-h intervals. The animals were also pretreated
with control vehicle, DRM02 or the corticosteroid
clobetasol 2 h prior to each imiquimod administration. Clobetasol was included in these experiments as
a clinically used, reference anti-psoriasis treatment
for comparison with DRM02. In these studies, we
first investigated if DRM02 activity could affect clinical scores in imiquimod-induced psoriasiform
lesions on mouse dorsal skin. To this end, we
employed an established scoring system to assess
skin inflammation, based on the clinically used
Psoriasis Area and Severity Index (PASI).31 Skin
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plaques (scored 0–4) and erythema (scored 0–4)
were evaluated independently, with higher scores
indicating increased severity. DRM02 gel applied
twice daily for 7 days led to significantly lower imiquimod-induced psoriasiform scores (Figure 7a),
without observable deleterious systemic effects, as
evidenced by unaltered body, draining lymph node,
and spleen weights (Supplemental Figure 4).
Clobetasol similarly prevented the clinical skin
changes produced by imiquimod. However, clobetasol treatment was associated with significant systemic outcomes, including a 6% decrease in body
weight, as well as significant reductions in relative
lymph node and spleen weights (Supplemental
Figure 4). As an additional test of the effects of
DRM02 on inflammation, we measured changes in
ear thickness associated with exposure to imiquimod. Topical application of DRM02 either once or
twice daily onto ears just prior to imiquimod treatment significantly reduced ear swelling to a similar
extent to that observed with clobetasol (Figure 7b).
We also harvested tissues from treated animals, to
assess changes in inflammatory gene expression 6 h
after the last imiquimod dose. We analyzed a panel
of cytokines and chemokines associated with inflammation and/or psoriasis, and observed significant
increases in mRNA and protein levels of the propsoriatic cytokines IL-17a, IL-17 f and IL-22 in imiquimod-treated skin relative to those in skin of naive
mice. These imiquimod-induced increases were
mitigated by treatment with DRM02 or clobetasol
(Figure 7c,d; Supplemental Tables S1 and S2).
Together, these observations indicate that DRM02
significantly improves psoriasiform clinical scores in
the imiquimod mouse model, likely through
mechanisms that involve interference with production of pro-inflammatory mediators.
Discussion
In these studies, we have demonstrated a wide range
of anti-inflammatory properties exhibited by
DRM02, a novel and selective phosphodiesterase
PDE4 inhibitor. During in vitro profiling, we
observed that DRM02 also reduced phosphotransferase activity present in ILK immunoprecipitates.
The role of ILK in inflammation appears to be complex. For example, ILK is necessary for neutrophil
trafficking to sites of inflammation and activation of
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epithelial inflammatory signaling in experimental
colitis mouse models.32 ILK is also important for
leukocyte chemotaxis and immune cell trafficking,
as ILK-deficient thymic T lymphocytes exhibit
reduced chemotaxis to the chemokines CXCL12
and CCL19.33 In contrast, cytokine production and
proliferation of B-lymphocytes following LPS challenge does not require ILK.34 Similarly, our studies
found that ILK is neither required in epidermal
keratinocytes for responses to IL-1α and TNFα, nor
for the anti-inflammatory effects of DRM02 in these
cells, suggesting that DRM02 may exert its antiinflammatory effects predominantly through PDE4
modulation.
Cyclic AMP plays pivotal roles in all the cell types
that contribute to the pathophysiology of inflammatory diseases in the skin and other organs.35 For
example, leukocytes from individuals with atopic
dermatitis exhibit increased phosphodiesterase
activity and cAMP degradation, resulting in activation of pro-inflammatory cascades.36 Thus, the pharmacological modulation of phosphodiesterases has
been identified as an important therapeutic strategy
in the management of mild-to-moderate skin
inflammatory conditions.
In humans, over one hundred forms of cyclic
nucleotide phosphodiesterases have been identified.
Amongst individual phosphodiesterase families, the
C-terminal catalytic domains are conserved and
determine substrate recognition and binding selectivity for inhibitors.37 Within the PDE4 family, the
Q2 domain contains a unique pocket that can
accommodate a water molecule, further contributing
to the ability of specific small molecules to selectively
interact with a given PDE4 isoform(s).36 Whether
DRM02 binds PDE4 isoforms through this watercontaining pocket remains an important area for
future research, which may also aid in the development of additional analogues with improved potency
and activity.
PDE4 inhibitors increase intracellular cAMP
levels, leading to impaired transcription of proinflammatory NF-κB target genes, through
mechanisms that involve protein kinase
A activation, up-regulation of cAMP responsive
element binding protein (CREB) and CRE-driven
gene transcription.12,38 Our experiments using
293Luc reporter cells showed that DRM02
decreased NF-κB transcriptional activity in cells
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Figure 7. DRM02 ameliorates imiquimod-induced inflammation.
Dorsal mouse skin received control (placebo) gel, DRM02 gel or clobetasol cream 2 h prior to daily treatment with topical imiquimod
(5% cream, 62.5 mg/mouse). Six hours after the third imiquimod application, treated skin was harvested and processed to obtain
RNA or protein lysates. (a) Imiquimod cream was applied to shaved dorsal skin and to one ear daily for 6 days. Clinical scores (0–8)
were recorded daily for imiquimod-dosed mice given no other treatment (∎), control (placebo) gel twice daily (▭), DRM02 gel
applied once (▽) or twice (◯) daily or clobetasol cream (▴) administered once daily. (b) Mice were treated as in (a), and Day-6 ear
thickness measurements were obtained. The results are expressed as the percent change from baseline (Day 0). (c) Expression levels
for the indicated mRNA species measured by RT-qPCR. The results were normalized to values obtained for the housekeeping gene
RPLP0, and are presented relative to normalized qPCR values obtained from mRNA isolated from treatment-naïve mice. (d) Levels of
the indicated cytokines in skin protein lysates were measured using the Luminex system (IL-17A, IL-17F) or ELISA (IL-22), and
normalized to sample protein concentration. Mean values + SD (5 mice per group) are shown. *P < .05 versus vehicle control (oneway ANOVA and Dunnett’s multiple comparisons test).

stimulated with TNFα. PDE4 inhibitors exhibit cell
type- and stimulus-specific effects on NF-κB pathways. For example, apremilast reportedly interferes
with NF-κB transcriptional activity in THP-1 and

Jurkat cells without altering the ability of this transcription factor to translocate to the nucleus.12 In
contrast, PDE4 inhibition by rolipram in human
leukemia cells activated by TLR7/8 and TLR9-
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agonists decreased IκBα phosphorylation and NFκB p65 nuclear translocation.39 Our studies showed
that DRM02 exhibits anti-inflammatory activity in
multiple cultured cell types exposed to a variety of
stimuli without detectable cytotoxicity. DRM02
interfered with activation of keratinocyte and
immune cell responses to IL-1 and TNFα, two key
pro-inflammatory cytokines, and also reduced
immune cell responses to TLR ligands.
Inflammatory cues stimulate keratinocytes to
express ICAM-1, which promotes leukocyte
recruitment to the skin, thereby playing a pivotal
role in promoting and amplifying inflammatory
responses.40 DRM02 decreased up-regulation of
ICAM-1 induced by TNFα or TNFα/IFNγ combinations in human HaCaT keratinocytes and THP1 monocyte-like cells. DRM02 also inhibited
ICAM-1 expression in response to TLR2, TLR3
and TLR4 stimulation in THP-1 cells. In contrast,
DRM02 had no detectable effect on ICAM-1 upregulation in response to IFNγ alone. Whereas
TNFα and TLR ligands exert many of their biological effects through NF-κB activation,41 IFNγ preferentially stimulates signaling through JAK/STAT
pathways. These observations further underline
the possibility that the anti-inflammatory activity
of DRM02 may be predominantly associated with
NF-κB modulation. An important area for future
research will be to determine the mechanisms
involved in DRM02 regulation of NF-κB activity
in epidermal keratinocytes and other cell types
associated with skin inflammation.
DRM02 attenuated IL-1α-induced increases in
GM-CSF expression in both mouse and human keratinocytes. GM-CSF is highly expressed in skin
regions affected by atopic dermatitis42 or
psoriasis.43 Importantly, GM-CSF may foster eosinophil, monocyte-macrophage and Langerhans cell
viability and activity in chronic inflammatory skin
lesions, thus contributing to persistence of disease.44
The prominent inhibitory effects of DRM02 on the
expression of GM-CSF and other inflammatory
mediators in epidermal keratinocytes may be a key
mechanism involved in the observed efficacy of
DRM02 against inflammatory skin diseases.
In vivo, the TLR4 ligand LPS elicits responses
that reflect activation of the innate immune system, such as release into the bloodstream of a wide
variety of cytokines and chemokines, mainly
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produced by monocytes.26 Significantly, DRM02
mitigated LPS-induced increases in TNFα, GMCSF and IFN-γ serum levels, and increased those
of the anti-inflammatory cytokine IL-10. These
effects are consistent with the known mode of
action of other PDE4 inhibitors, which induce
PKA activation via cAMP, leading to IL-10 expression and inhibition of NF-κB,9 further suggesting
that DRM02 likely reduces inflammatory
responses in vivo through pathways that involve
PDE4 inhibition. In these experiments, there were
no discernible adverse side effects of DRM02
administration. However, although DRM02 has
shown marked selectivity for PDE4 enzymes in
pharmacological profiling assays, detailed pharmacodynamic characterization using a range of
DRM02 doses in mice will be an important area
for future studies, to rule out possible off-target
effects under the conditions of our experiments.
Topical DRM02 treatment in mice reduced the
acute, edematous reaction to PMA, the antigenspecific Th2 type immune contact hypersensitivity
response to FITC, and the development of Th17
immune pathway-related psoriasiform lesions elicited by the TLR7/8 agonist IMQ. DRM02 also
reduced mRNA and protein levels of IL-17A, IL17 F, and IL-22 in the skin. These cytokines,
released by T lymphocytes and natural killer
cells, trigger innate immunity responses in epithelial cell types, but with distinct response patterns.
IL-17 induces inflammatory-type responses,
whereas IL-22 predominantly influences epithelial
cell differentiation.45,46 Importantly, DRM02
exerted anti-inflammatory effects in a variety of
mouse models of inflammation, without detectable
negative systemic effects. In contrast, we found
that adverse systemic effects accompanied clobetasol treatment in IMQ-induced psoriasiform
inflammation, including weight loss and immunesystem organ size alterations.
Chronic inflammatory skin disorders, such as
psoriasis and atopic dermatitis, are associated with
impaired skin barrier function. For example, imiquimod-induced psoriasis in mouse models is characterized by increased transepidermal water loss,
indicative of impairment in the barrier function of
the skin.47 In this and other preclinical models, interference with inflammatory pathway activation alleviates dermatitis symptoms and skin barrier
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dysfunction,47 and a key question to address in the
future is whether the anti-inflammatory properties
of DRM02 contribute to the restoration of skin barrier capacity. Overall, however, our studies have
shown that DRM02 is a novel anti-inflammatory
drug that exhibits activity in a wide array of in vitro
and in vivo models of skin inflammation elicited by
distinct insults and stimuli. Importantly, the antiinflammatory activity that DRM02 exhibited in
these models was comparable or superior to that
observed with commonly used therapeutic corticosteroids, such as dexamethasone and clobetasol.
Chronic inflammatory skin diseases, such as
psoriasis and atopic dermatitis, affect many individuals. Major therapies for these disorders consist
of topical administration of costicosteroids, vitamin D analogues, retinoids, and calcineurin
inhibitors.48 However, these therapies are not
equally effective for all patients, and can be associated with severe undesired side effects. For
example, chronic topical corticosteroid use produces skin atrophy, delayed wound healing, and
increased susceptibility to infections.49,50 Further,
systemic corticosteroid distribution following topical administration can result in hypothalamicpituitary axis suppression.49,50 These limitations
have spurred the development of novel therapies,
such as those that selectively target PDE4.
PDE4 inhibition reduces cellular cAMP hydrolysis, which in turn interferes with synthesis and
release of pro-inflammatory cytokines, including
TNFα, IFNγ and various interleukins.51 Clinically
used oral PDE4 inhibitors, such as apremilast, are
very effective, but are still associated with gastrointestinal and neurological adverse effects.48,52,53
Several small molecule PDE4 inhibitors for topical
use are currently at various stages of development.
For example, CHF6001 is a potent PDE4 inhibitor
administered by inhalation, and used for inflammatory pulmonary diseases.54 Preclinical studies have
shown that CHF6001 interferes with NF-kB nuclear
translocation and reduces oxidative stress in cultured
epidermal keratinocytes, although its cutaneous antiinflammatory effects in vivo have yet to be
reported.53 E6005, another novel PDE4 inhibitor
developed for topical use, suppressed proinflammatory cytokine production in human lymphocytes in vitro, exhibited anti-inflammatory effects
in mouse models of atopic dermatitis, and showed

acceptable tolerability in randomized controlled
trials.55 Crisaborole is a potent boron-based PDE4
and TNFα release inhibitor in PBMC (IC50 = 0.49–5.0 μM).56,57 Topically administered 2% crisaborole
ointment is well tolerated and has been approved for
the treatment of mild or moderate atopic
dermatitis.56,57 Important features of crisaborole in
these trials were its low systemic exposure and mild
treatment-related adverse events that spontaneously
resolved in 16%-57% of patients.58,59 Further, crisaborole reduced expression of inflammatory mediators and improved skin barrier function in atopic
dermatitis patients,60 indicating that PDE4 inhibition
may be an effective approach to restore the epidermal barrier, at least under some circumstances.
Our studies demonstrate that topical DRM02 is
well tolerated and exhibits effective antiinflammatory activity in a variety of cutaneous
inflammatory mouse disease models. An exploratory,
double-blinded, randomized, within-subject control
Phase-II clinical study (NCT01993420) evaluated
0.25% DRM02 topical gel given twice daily for six
weeks to 21 adult individuals with atopic dermatitis.
DRM02 treatment was well tolerated locally, and
without any discernible systemic effects. Both
DRM02 and the control gel produced marked reductive effects on target lesion scores, potentially masking any DRM02-invoked pharmacological activity.
Given that the preclinical pharmacological profile
of DRM02 is consistent with pronounced selectivity
for PDE4, the development of DRM02 formulations
optimized for topical delivery in humans may thus
constitute an effective alternative therapeutic
approach to the use of corticosteroids and other
current treatments for inflammatory skin conditions.

Materials and methods
Ethics approvals

All studies using human PBMC were approved by
the ethics committee of QLT Inc. Experiments using
human PBMC were conducted with blood drawn
from healthy adult human male and female volunteers under written informed consent, and in accordance with the Helsinki Declaration of 1975. All
animal experiments received ethics approvals in
accordance with guidelines and regulations of the
Canadian Council on Animal Care. Experiments
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using ILK-expressing and ILK-deficient primary
keratinocytes were approved by the University of
Western Ontario Animal Care Committee
(Protocol No. 2015–21). Study protocols for imiquimod-induced inflammation in vivo studies were
reviewed and approved for compliance with the
rules and regulations of the MD BioSciences
Committee for Ethical Conduct in the Care and
Use of Laboratory Animals. All other inflammation
animal model studies were approved by the Animal
Care Committee of QLT, Inc., Vancouver, Canada,
as follows: LPS systemic inflammation studies,
Protocol No. ACC05-013; PMA inflammation studies, Protocol No. ACC05-002; FITC-contact hypersensitivity studies, Protocol No. ACC06-011.
In vitro DRM02 activity profiling

DRM02 (10 μM) biochemical profiling assays were
conducted under contract, using The Safety Profile
panel (Eurofins Cerep, Poitiers, France) against 76
enzyme and 112 receptor binding targets. Further,
the activity of 355 different kinases assessed DRM02
at 10 μM using the KINOMEscan™ (Eurofins
DiscoveRx Corporation, San Diego, CA). The compound (1, 10 μM) was also tested against selected 57
active kinase and three phosphatase targets by
SignalChem Lifesciences Corporation (Richmond,
Canada). Following initial determination, DRM02
was re-assayed against U-937 cell-derived PDE4
(Eurofins Cerep) to obtain definitive IC50 values.
DRM02 was subsequently tested against available
representative isoforms of different human PDE
families, using recombinant human PDE proteins,
except for PDE5 and PDE6 which were prepared
from human and bovine tissues, respectively
(Eurofins Cerep).
ILK biochemical assays and selectivity profiling
studies were conducted with recombinant ILK prepared as a glutathione-s-transferase (GST)-fusion
protein expressed in Hi-5 insect cells using
a baculovirus expression system,61 and are detailed
in the Supplemental Information section.
Human cell inflammatory response studies

For all cell culture experiments, DRM02, FK506
and dexamethasone were solubilized in 100% tissue culture-grade dimethyl sulfoxide (DMSO).
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To obtain PBMC, blood was drawn from healthy
adult human male and female volunteers under
informed consent on the day of experiments. PBMC
were isolated using Ficoll-Hypaque Plus (Cat. No.
17–1440-02, GE Healthcare, Little Chalfont, UK) density centrifugation and re-suspended in RPMI 1640
medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 1% penicillin/streptomycin,
1% GlutaMAX, 20 mM HEPES, 1 mM sodium pyruvate and 0.05 mM 2-mercaptoethanol (2-ME).
PBMC (1.5 x 106 cells/ml) were added to 96-well flatbottom plates (0.1 ml/well). To stimulate monocyte
cytokine production, PBMC were treated with LPS
(10 ng/ml) plus IFNγ (33 ng/ml). To activate
T lymphocytes, PBMC were incubated with phytohemagglutinin (1 μg/ml). Test compounds were solubilized in DMSO. Culture wells contained 0.15%
DMSO, using an assay volume of 0.2 ml per well.
Triplicate determinations were conducted for each
test concentration. Incubations were carried out at
37°C for 48 h under 5% CO2.
THP-1 monocytes (American Type Culture
Collection) were maintained in RPMI medium supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 1% GlutaMAX, 20 mM HEPES
buffer and 0.05 mM 2-ME. For experiments to measure cytokine production, THP-1 cells (1 x 105 cells/
ml) were seeded into 96-well flat-bottom plates
(0.2 ml per well). To stimulate cytokine production,
cells were treated with E. coli 0111:B-4 LPS (10 ng/ml)
plus IFNγ (100 ng/ml) for 48 h. To assess effects on
ICAM-1 expression, THP-1 cells (1 x 105 cells/ml)
were seeded into 12-well plates (1 ml/well) and incubated with DRM02 (10 μM) for 1 h. TNFα (10 ng/ml),
IFNγ (10 ng/ml) or Toll-like receptor (TLR) agonists
PGN (TLR2, 1 μg/ml), poly I: C (TLR3, 5 μg/ml) or
LPS (TLR4, 1 μg/ml) were then added, with a final
DMSO concentration of 0.25% in 1 ml. After 48 h of
culture, cells were washed twice with PBS and stained
with phycoerythrin (PE)-conjugated mouse antihuman ICAM-1 (CD54) monoclonal antibody
(HA58 antibody from eBiosciences; ThermoFisher
Cat. No. 12–0549-42). A FACScan flow cytometer
(BD Biosciences) was used to acquire signals from
10,000–15,000 cells per sample, analyzed using
CellQuest software, and mean channel fluorescence
intensity (MCFI) values were obtained. To account
for inter-experiment variability, THP-1 ICAM-1
levels were expressed as a ratio of the MCFI value
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obtained for stimulated cells, relative to the MCFI
result determined for non-stimulated cells.
Normal human epidermal keratinocytes (NHEK)
(Cat. No. 00192907, Lonza, Basel, Switzerland) were
cultured in serum-free medium (KGM) prepared
using KC basal medium (KBM) supplemented with
KGM SingleQuots and 2 µM hydrocortisone. The
medium was changed every 2–3 days and cells were
subcultured when 80–90% confluence was attained.
For experiments, NHEK at passage 2–4 were seeded
at 8 × 103 cells/ml into 96-well microtiter plates in
0.2 ml per well. The final culture concentration for
DMSO was 0.15%. Cells were maintained without
hydrocortisone 24 h prior to and throughout the
experimental phase.
HaCaT cells,62 kindly provided by Dr. N.E. Fusenig
(German Cancer Research Center), were maintained
in DMEM supplemented with 10% FBS, 1 mM
sodium pyruvate and 20 mM HEPES buffer. Cells
were passaged when 80–95% confluence was reached,
and plated into 12-well plates at 5 × 105 cells/well for
experiments. For surface ICAM-1 expression studies,
test compounds were added 1 h before stimulation
with TNFα (10 ng/ml) or TNFα plus IFNγ (2.5 ng/ml)
with a final DMSO concentration of 0.5%. The effects
of DRM02 on surface expression of ICAM-1 induced
by IFNγ (2.5 ng/ml), IFNγ plus IL-1β (100 ng/ml), as
well as IL-1β plus TNFα, were also evaluated. After
48 h of treatment, cells were washed twice with PBS,
detached using trypsin, stained with HA58 PEconjugated mouse anti-human ICAM-1 antibody
and analyzed by flow cytometry. For each experimental condition, at least 5,000–10,000 cells were analyzed. HaCaT cell surface ICAM-1 levels were
expressed as a percentage of the result for drugtreated cytokine-stimulated cells versus the MCFI
determination obtained for vehicle-treated cytokinestimulated cells, evaluated in parallel.
Phorbol-induced dermatitis skin inflammation
studies

Methods employed for testing against systemic LPSinduced endotoxemia and skin inflammation triggered by phorbol ester were as described.63 While
under isoflurane anesthesia, baseline ear thickness
measurements were taken from female BALB/c
mice (Charles River Canada, St. Constant, Canada)
of approximately 8 weeks of age, using a micrometer

(Mitutoyo Corporation, Mississauga, Canada). Ten
μL of a 0.02% PMA solution in 100% acetone were
applied onto each side of the test ear (4 μg PMA/ear).
Three hours later, animals received 10 μL of the test
agent diluted in 3% DMSO/97% acetone on each
side of the ear. Ear thickness was re-measured 24 h
after PMA application. Technical staff blinded to the
identity of the test articles applied conducted all
treatments and measurements.
Contact hypersensitivity (CHS) skin inflammation
studies

A mouse Th2-type FITC-CHS response model was
employed,27,64 with minor modifications. Female
BALB/c mice of approximately 8 weeks of age were
used. The abdominal region of each mouse was
shaved and 400 μL of 0.5% fluorescein isothiocyanate
(FITC) dissolved in acetone:dibutyl phthalate (1:1 v/
v, hereafter termed FITC solution) were applied onto
the abdomen on Day 0 and Day 1. FITC sensitization
was repeated on Days 14 and 15, using 400 μL of
FITC solution. Prior to FITC challenge (Day 20),
mice were anesthetized using isoflurane, baseline
ear thickness measurements were obtained and
10 μL of FITC solution maintained at 4°C were
applied to each side of one ear. Two hours later,
each animal received 5 μL of the control vehicle
(15% DMSO in acetone) or test agent (dissolved in
the same mixture of DMSO and acetone) on each
side of the same ear. Ear thickness was re-measured
24 h following FITC challenge. All treatments and
measurements were conducted by personnel blinded
to the identity of test substances applied.
Imiquimod-induced skin inflammation model
Development of psoriasis-like inflammation driven by the IL-23/IL-17 immune axis is produced
in mouse skin with repeat topical application of
the TLR 7/8 agonist imiquimod.29,30 For these
experiments, conducted by MD Biosciences
(Zurich, Switzerland) under contract, the backs of
9–10 weeks old female BALB/c mice were shaved
and 5% imiquimod cream (62.5 mg; Aldara
Cream, Meda, Dubai, UAE) was applied to an
area of approximately 10 cm2, once daily for
three days. The anti-inflammatory treatments consisted in ~0.3 ml of placebo gel, 0.25% DRM02 gel,
or clobetasol propionate (0.05% Dermovate cream;
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GlaxoSmithKline, Uxbridge, UK). Clobetasol
served as a comparative anti-inflammatory treatment, and was selected on the basis that this
potent corticosteroid is an approved and clinically
effective topical agent to treat psoriasis. Topical
clobetasol effectively suppresses disease activity in
the imiquimod psoriasis-like mouse model.65 For
biomarker studies, imiquimod cream was applied
at t = 2, 26, and 50 h, whereas control gel, 0.25%
DRM02 gel or clobetasol cream (0.3 ml per 10 cm2
surface area) were given 2 h prior to each imiquimod application. Animals were euthanized 6 h
after the final imiquimod dose. One section from
treated skin was placed in RNAlater for mRNA
analyses. qPCR was conducted using commercial
primer pairs (ThermoFisher Scientific) with skin
mRNA levels expressed by normalization of sample values to the qPCR result obtained in each
sample for the large sub-unit of ribosomal protein
P0 (Rplpo) housekeeping gene. A 2.5-fold or
greater increase in the relative level of a given
mRNA species in imiquimod-treated versus naïve
skin was considered significant. A second skin
section was snap-frozen in liquid nitrogen for subsequent protein biomarker analysis using
a Multiplex system (Luminex Corporation,
Austin, TX, USA) or by ELISA (IL-22, Cat. No.
LS-F26459, eBioscience Reagents, ThermoFisher
Scientific). Biomarker levels were normalized to
skin extract protein concentration as determined
with Pierce Micro BCA protein assays (Cat. No.
23235, ThermoFisher Scientific).
To evaluate treatment effects on clinical symptoms, 62.5 mg of imiquimod cream was applied
once daily starting on Day 0 onto pre-shaved back
skin. To induce ear edema, 10 μL of imiquimod
cream was applied on to the right ear daily. Right
ear thickness measurements were conducted on Day
0 before the first imiquimod application and on Day
6, using a digital caliper. The control gel was given
twice daily, 0.25% DRM02 gel applied either once or
twice daily and clobetasol cream once daily at
a volume of 300 μL for the dorsal skin site and
10 μL for the ear. For mice receiving test items
twice daily, these treatments were approximately
6 h apart with the first application given 2 h prior
to and the second 4 h after each imiquimod dose.
Body weights, as well as skin clinical plaque (0–7)
and erythema (0–4) scores were recorded daily,
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using an established scale (MD BioSciences,
Zurich, Switzerland). On Day 6, animals were euthanized by CO2 overdose 6 h after the final imiquimod
application. Spleen and inguinal lymph node
weights of individual mice were recorded.
Additional procedures

The Supplemental Information section describes the
following: suppliers of growth factors, cell stimulants, other inhibitors and chemicals; methods for
isolation and cytokine stimulation of primary mouse
epidermal keratinocytes; assays to determine human
cell viability and proliferation; cultured human cell
cytokine/chemokine quantification; NF-κB reporter
assays; systemic LPS endotoxemia mouse model studies. All mandatory laboratory health and safety
procedures were followed in the course of the experiments reported herein.
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